SEC Form 4 · accession 0001209191-15-086482
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David D Chang
Officer — EVP, R&D, Chief Medical Off.
Period of report
Dec 17, 2015
Accepted (ET)
Dec 21, 2015 · 8:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 17, 2015 | A | 18,500 | $0.00 | A | 25,404 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $63.87 | Dec 17, 2015 | A | 66,100 | A | — | Dec 16, 2025 | Common Stock | 66,100 | 66,100 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.